ARCHIVES

FDA News: FDA Approved A Supplemental New Drug Application For Nexavar Tablets (Sorafenib) For The Treatment Of Patients With Locally Recurrent Or Metastatic, Progressive, Differentiated Thyroid Carcinoma Refractory To Radioactive Iodine Treatment.

This article is from The Cancer Letter archive.

Vol. 39 No. 45 | December 17, 2013

Download PDF Visit The Full Archive

Related Articles

Consructio Needs Over Next Five Years Total Estimated $696 Million; NCI Share-$132 Million

January 19, 1979

DCCP Board Oks Fur New Concepts

July 17, 1981

ASCO, ONS Issue Standards For Safe Chemotherapy Administration

October 2, 2009

Obey Insists NCI Pressured IARC Into Softening Report On Benzene Risk

August 20, 1982

DCPC Board Approves New Intramural Laboratory for Diet And Nutrition; NCAB to Consider It Next

May 22, 1987

In Brief: Litton Bionetic’s New contract For Operation of FCRC Total $128.8 Million For Five Years

October 7, 1977